{
    "nct_id": "NCT03656835",
    "official_title": "A Pilot Study of Nanochip Technology for Monitoring Treatment Response and Detection of Relapse in Patients With Diffuse Large B-Cell Lymphoma",
    "inclusion_criteria": "* Histologically confirmed treatment naive DLBCL. Subtypes including high grade B-cell lymphoma, not otherwise specified (NOS) and de-novo DLBCL including germinal center B-cell type (GCB) and non-GCB subtypes.\n* Intent to receive entire care (treatment and follow-up) at Ohio State University (OSU).\n* Receiving treatment with curative intent.\n* Receiving planned 6 cycles of chemotherapy.\n* Ability to consent.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Transformed lymphomas.\n* DLBCL with leukemic presentation.\n* Primary central nervous system (CNS) lymphoma.\n* Participating in other clinical trial/ receiving experimental therapy.\n* Patients with a \"currently active\" second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, or confound data interpretation.\n* Pregnancy (positive serum or urine pregnancy test) or breast feeding.",
    "miscellaneous_criteria": ""
}